|
1
|
Riska A, Leminen A and Pukkala E:
Sociodemographic determinants of incidence of primary fallopian
tube carcinoma, Finland 1953–97. Int J Cancer. 104:643–645.
2003.PubMed/NCBI
|
|
2
|
Markman M, Webster K, Zanotti K, Kulp B,
Peterson G and Belinson J: Phase 2 trial of single-agent
gemcitabine in platinum-paclitaxel refractory ovarian cancer.
Gynecol Oncol. 90:593–596. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lorusso D, Di Stefano A, Fanfani F and
Scambia G: Role of gemcitabine in ovarian cancer treatment. Ann
Oncol. 17(Suppl 5): v188–v194. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stewart SL, Wike JM, Foster SL and Michaud
F: The incidence of primary fallopian tube cancer in the United
States. Gynecol Oncol. 107:392–397. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ajithkumar TV, Minimole AL, John MM and
Ashokkumar OS: Primary fallopian tube carcinoma. Obstet Gynecol
Surv. 60:247–252. 2005. View Article : Google Scholar
|
|
6
|
Hefler LA, Rosen AC, Graf AH, et al: The
clinical value of serum concentrations of cancer antigen 125 in
patients with primary fallopian tube carcinoma: a multicenter
study. Cancer. 89:1555–1560. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wethington SL, Herzog TJ, Seshan VE, et
al: Improved survival for fallopian tube cancer: a comparison of
clinical characteristics and outcome for primary fallopian tube and
ovarian cancer. Cancer. 113:3298–3306. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Rosen AC, Ausch C, Hafner E, et al: A
15-year overview of management and prognosis in primary fallopian
tube carcinoma. Austrian Cooperative Study Group for Fallopian Tube
Carcinoma. Eur J Cancer. 34:1725–1729. 1998.PubMed/NCBI
|
|
9
|
Riska A and Leminen A: Updating on primary
fallopian tube carcinoma. Acta Obstet Gynecol Scand. 86:1419–1426.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Papadimitriou CA, Peitsidis P, Bozas G, et
al: Paclitaxel- and platinum-based postoperative chemotherapy for
primary fallopian tube carcinoma: a single institution experience.
Oncology. 75:42–48. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gadducci A, Landoni F, Sartori E, et al:
Analysis of treatment failures and survival of patients with
fallopian tube carcinoma: a cooperation task force (CTF) study.
Gynecol Oncol. 81:150–159. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pectasides D, Pectasides E, Papaxoinis G,
et al: Primary fallopian tube carcinoma: results of a retrospective
analysis of 64 patients. Gynecol Oncol. 115:97–101. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Baekelandt M, Jorunn Nesbakken A,
Kristensen GB, Tropé CG and Abeler VM: Carcinoma of the fallopian
tube. Cancer. 89:2076–2084. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tresukosol D, Kudelka AP, Edwards CL,
Fromm GL, Mante R and Kavanagh JJ: Primary fallopian tube
adenocarcinoma: clinical complete response after salvage treatment
with high-dose paclitaxel. Gynecol Oncol. 58:258–261. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dunton CJ and Neufeld J: Complete response
to topotecan of recurrent fallopian tube carcinoma. Gynecol Oncol.
76:128–129. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsuo K, Lin YG, Roman LD and Sood AK:
Overcoming platinum resistance in ovarian carcinoma. Expert Opin
Investig Drugs. 19:1339–1354. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van Moorsel CJ, Pinedo HM, Veerman G, et
al: Mechanisms of synergism between cisplatin and gemcitabine in
ovarian and non-small-cell lung cancer cell lines. Br J Cancer.
80:981–990. 1999.
|
|
18
|
Rose PG, Mossbruger K, Fusco N, Smrekar M,
Eaton S and Rodriguez M: Gemcitabine reverses cisplatin resistance:
demonstration of activity in platinum- and multidrug-resistant
ovarian and peritoneal carcinoma. Gynecol Oncol. 88:17–21. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nagourney RA, Brewer CA, Radecki S, et al:
Phase II trial of gemcitabine plus cisplatin repeating doublet
therapy in previously treated, relapsed ovarian cancer patients.
Gynecol Oncol. 88:35–39. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tewari D, Monk BJ, Hunter M, Falkner CA
and Burger RA: Gemcitabine and cisplatin chemotherapy an active
combination in the treatment of platinum-resistant ovarian and
peritoneal carcinoma. Invest New Drugs. 22:475–480. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brewer CA, Blessing JA, Nagourney RA,
Morgan M and Hanjani P: Cisplatin plus gemcitabine in
platinum-refractory ovarian or primary peritoneal cancer: a phase
II study of the Gynecologic Oncology Group. Gynecol Oncol.
103:446–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bozas G, Bamias A, Koutsoukou V,
Efstathiou E, Gika D, Papadimitriou CA and Dimopoulos MA: Biweekly
gemcitabine and cisplatin in platinum-resistant/refractory,
paclitaxel-pretreated, ovarian and peritoneal carcinoma. Gynecol
Oncol. 104:580–585. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rose PG: Gemcitabine reverses platinum
resistance in platinum-resistant ovarian and peritoneal carcinoma.
Int J Gynecol Cancer. 15(Suppl 1): 18–22. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Griffiths RW, Zee YK, Evans S, et al:
Outcomes after multiple lines of chemotherapy for
platinum-resistant epithelial cancers of the ovary, peritoneum, and
fallopian tube. Int J Gynecol Cancer. 21:58–65. 2011. View Article : Google Scholar : PubMed/NCBI
|
